Chargement en cours...
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic co...
Enregistré dans:
| Publié dans: | Int J Mol Sci |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5979390/ https://ncbi.nlm.nih.gov/pubmed/29670046 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19041232 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|